Filing Details
- Accession Number:
- 0001209191-21-058051
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2021-09-29 16:12:19
- Reporting Period:
- 2021-09-27
- Accepted Time:
- 2021-09-29 16:12:19
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1679082 | Myovant Sciences Ltd. | MYOV | Pharmaceutical Preparations (2834) | 000000000 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1714080 | Camilo Juan Ferreira Arjona | C/O Myovant Sciences Inc. 2000 Sierra Point Parkway, 9Th Floor Brisbane CA 94005 | Chief Medical Officer | No | Yes | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Shares | Acquisiton | 2021-09-27 | 7,000 | $7.78 | 178,329 | No | 4 | M | Direct | |
Common Shares | Disposition | 2021-09-27 | 7,000 | $24.32 | 171,329 | No | 4 | S | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | M | Direct | |
No | 4 | S | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Shares | Stock Option (Right to Buy) | Disposition | 2021-09-27 | 7,000 | $0.00 | 7,000 | $7.78 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
159,100 | 2027-08-14 | No | 4 | M | Direct |
Footnotes
- Shares sold pursuant to a 10b5-1 trading plan.
- The shares were sold at prices ranging from $24.01 to $24.96. The reporting person will provide to the SEC, the issuer or security holder of the issuer, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- 1/4 of the common shares underlying this option vested on August 15, 2018, and 1/16 of the common shares underlying this option vest each quarter thereafter, provided the Reporting Person has provided continuous service to the Issuer or its affiliates on each such date.